Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

5 Key Things to Know About His Grade 2 Hamstring Strain

Published

on

Luka Doncic

LOS ANGELES — Los Angeles Lakers superstar Luka Doncic will miss the remainder of the 2025-26 NBA regular season after suffering a Grade 2 left hamstring strain, dealing a significant blow to the team’s playoff positioning and his MVP candidacy just weeks before the postseason begins.

Luka Doncic
Luka Doncic

The Slovenian guard, who has led the NBA in scoring much of the season, went down in the third quarter of the Lakers’ 139-96 loss to the Oklahoma City Thunder on April 2. He grabbed his left hamstring after a spin move near the paint and did not return, finishing with 12 points, four rebounds and seven assists in 26 minutes. An MRI the following day confirmed the partial tear.

Here are five essential things to know about Doncic’s injury as the Lakers prepare for the 2026 NBA Playoffs without their primary offensive engine.

1. It’s a Grade 2 hamstring strain with a typical 3-to-6 week recovery timeline. A Grade 2 strain involves a partial tear of the muscle fibers, causing significant pain, swelling and weakness. Injury analysts note the average recovery time hovers around 35 days, though it can range from three to six weeks or longer depending on the exact location and severity. The Lakers have ruled Doncic out for the final stretch of the regular season, with only five games remaining as of early April. Playoffs begin April 18, giving him a narrow window if healing progresses faster than expected.

2. Doncic is seeking specialized treatment in Europe to expedite his return. After consulting with Lakers doctors and his personal medical team, Doncic traveled to Spain for an injection procedure and advanced rehabilitation aimed at accelerating healing. Agent Bill Duffy confirmed the move, stating the goal is to maximize the chance of a playoff return. Reports indicate he has already completed phase one of his recovery program and is responding well, though no firm timetable has been set. Lakers coach JJ Redick described Doncic as being in “relatively good spirits” and attacking rehab aggressively.

Advertisement

3. The injury creates a major power vacuum for the Lakers in the Western Conference. With Austin Reaves also sidelined by an oblique strain, the Lakers are without two of their top offensive creators heading into the postseason. The team sits third in the West with a 50-27 record, but the absence of Doncic — their leading scorer and playmaker — shifts heavy responsibility to LeBron James and a supporting cast that has struggled in recent blowout losses. Analysts say the injury dramatically alters playoff seeding scenarios and matchup projections across the conference.

4. It jeopardizes Doncic’s MVP case and individual award eligibility. Doncic entered April as a legitimate MVP candidate and frontrunner for the scoring title. However, missing the remainder of the regular season raises questions about the 65-game threshold required for most major awards. While the injury is unlikely to be classified as “season-ending” under NBA rules (which consider sidelining a player through at least May 31), his limited games could cost him All-NBA honors and weaken his MVP standing. Betting markets quickly removed him from contention following the diagnosis.

5. History suggests a rushed playoff return carries significant risk. Recent NBA data on Grade 2 hamstring strains shows players often struggle to regain full explosiveness quickly. Returning too soon can lead to re-injury or diminished performance in high-stakes playoff games. If Doncic does suit up for the first round, he would be defying typical recovery patterns for this type of injury. The Lakers must balance the desire for their star’s presence against the long-term health of a player central to the franchise’s future.

The timing could hardly be worse for the Lakers. Doncic had been dominant all season, carrying the offense while James managed his own workload. His absence forces adjustments in offensive schemes, increased minutes for role players and potentially altered defensive strategies. LeBron James called the injury “the last thing you want to see,” especially for an MVP candidate on a contending team.

Advertisement

Fan reaction has been a mix of concern and cautious optimism. Social media buzzed with debates over whether Doncic should attempt a return even at less than 100 percent or if the team should prioritize his long-term health. Some pointed to past examples of stars playing through hamstring issues with mixed results.

Medical experts emphasize that hamstring strains, particularly in explosive athletes like Doncic, require careful management. The muscle group is prone to recurrence if not fully healed, and the high-speed, stop-start nature of NBA basketball amplifies the risk.

For the Lakers, the injury underscores broader roster construction questions. Reliance on star power has defined recent seasons, and the current crisis highlights vulnerabilities when key pieces go down. Depth will be tested in the coming weeks as the team fights for favorable playoff positioning without its Slovenian superstar.

Doncic, 27, has built a reputation for toughness and resilience throughout his career. He has overcome previous injuries, including earlier hamstring and groin issues this season, to deliver elite performances. His work ethic in rehab has been praised by teammates and coaches, providing a sliver of hope that he could factor into the postseason.

Advertisement

As April 12 approaches, updates from Europe and the Lakers’ training facility will be closely monitored. Any sign of accelerated healing could shift playoff narratives, while prolonged recovery might force the Lakers into an underdog role against stronger Western Conference opponents.

The broader NBA landscape feels the ripple effects. A diminished or absent Doncic changes series previews, betting lines and championship odds. Teams like the Thunder, who delivered the blowout in which he was injured, could see improved paths forward.

Doncic’s situation also reignites discussions about NBA scheduling, load management and the 65-game rule for awards. Some argue the compressed season and back-to-back demands increase injury risk for star players carrying heavy minutes.

For now, the focus remains on Doncic’s recovery. He continues daily rehabilitation, with the injection procedure in Spain representing a calculated gamble to compress the timeline. Lakers medical staff will work in tandem with his European team to monitor progress and avoid setbacks.

Advertisement

Whether he returns for the playoffs — and at what level — remains uncertain. What is clear is that the Lakers’ playoff hopes hinge on how effectively they adapt without their generational talent and whether Doncic can defy recovery odds once more.

As the regular season winds down, all eyes turn to Los Angeles for the next injury update on one of the NBA’s most dynamic stars. The 2026 postseason may look very different depending on Luka Doncic’s availability.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Kimbell Royalty Partners: Permian Basin Acquisition Slightly Increases Its Oil Cut

Published

on

Kimbell Royalty Partners: Permian Basin Acquisition Slightly Increases Its Oil Cut

Kimbell Royalty Partners: Permian Basin Acquisition Slightly Increases Its Oil Cut

Continue Reading

Business

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

Published

on

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study


J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

Continue Reading

Business

IAEA reports drone strike damage at Zaporizhzhia nuclear plant

Published

on


IAEA reports drone strike damage at Zaporizhzhia nuclear plant

Continue Reading

Business

ZenaTech: I Like The Story, But Not The Numbers

Published

on

ZenaTech: I Like The Story, But Not The Numbers

ZenaTech: I Like The Story, But Not The Numbers

Continue Reading

Business

J&J’s apalutamide cuts prostate cancer death risk by 20%

Published

on


J&J’s apalutamide cuts prostate cancer death risk by 20%

Continue Reading

Business

Silicom: The Market Is Still Pricing In A Cycle That Already Ended (NASDAQ:SILC)

Published

on

Silicom: The Market Is Still Pricing In A Cycle That Already Ended (NASDAQ:SILC)

This article was written by

Wail Shudar, M.S., is a quantitative investor and AI professional with over a decade of experience in the technology sector. A Harvard University alumnus with advanced degrees in Computer Science and Data Science, Wail possesses a deep technical understanding of the machine learning architectures and data ecosystems currently transforming the global economy. Professionally, Wail has spent 10+ years as an AI/ML specialist, providing him with the unique ability to distinguish between sustainable technological innovation and market hype. To complement his technical background, he is currently a CFA candidate, focusing on the integration of institutional-grade fundamental analysis with algorithmic rigor. Since 2015, he has successfully managed portfolios using data-driven systematic strategies, utilizing a “quantamental” approach that leverages big data to identify alpha in the technology and biotechnology sectors. On Seeking Alpha, Wail focuses on identifying high-growth stocks where AI-driven breakthroughs act as a primary catalyst for valuation expansion. His primary mission is to demystify complex technical sectors for the broader investing community. By translating intricate data science concepts into actionable investment theses, he provides readers with a systematic framework for navigating volatile growth markets. Wail aims to bridge the gap between Silicon Valley engineering labs and Wall Street valuation models, offering a technical edge to fundamental investors.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SILC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Jobs report on tap for soaring US stocks as rate path, bond yields eyed as risks

Published

on

Jobs report on tap for soaring US stocks as rate path, bond yields eyed as risks


Jobs report on tap for soaring US stocks as rate path, bond yields eyed as risks

Continue Reading

Business

IPO Calendar: Investors to get 2 mainboard public offers this week after a month of lull

Published

on

IPO Calendar: Investors to get 2 mainboard public offers this week after a month of lull
India’s primary market is set for an active week in the mainboard segment, with two public issues scheduled to open for subscription even as investor sentiment remains selective amid volatile equity markets and heightened global uncertainty. The spotlight will be on the IPOs of CMR Green Technologies and Hexagon Nutrition, which together aim to raise nearly Rs 770 crore.

The offerings come at a time when the IPO market has seen a lull for a few weeks in a tepid 2026. While several companies have secured regulatory approvals in recent weeks, many have put off their IPO plans due to market volatility.

The first issue to hit the market next week will be CMR Green Technologies. The company’s IPO will open on June 3 and close on June 5. The issue is priced in the range of Rs 182-192 per share and aims to raise Rs 630.9 crore. Equirus Capital is managing the offering.

CMR Green Technologies operates in the metal recycling and circular economy segment, manufacturing recycled aluminium and zinc products for automotive and industrial applications. The company counts several leading automotive manufacturers among its customers and is positioned to benefit from increasing adoption of recycled metals and sustainability-focused manufacturing practices.

Advertisement

The company is expected to attract investor interest given the growing focus on resource efficiency, electric vehicles and environmental regulations that are encouraging the use of recycled materials.


The second mainboard issue scheduled for next week is Hexagon Nutrition.
The IPO will open on June 5 and close on June 9. The company has fixed a price band of Rs 42-45 per share and plans to raise Rs 138.9 crore through an offer for sale of 3.09 crore shares. Since the issue is entirely an OFS, the company will not receive any proceeds from the public offering.Hexagon Nutrition is a research-driven nutrition company engaged in manufacturing micronutrient premixes, wellness and clinical nutrition products, therapeutic formulations and ready-to-use nutritional foods.

Founded in 1993, the company operates manufacturing facilities in Maharashtra, Tamil Nadu and Uzbekistan and exports products to more than 75 countries. Its products are sold through both business-to-consumer and business-to-business channels and include brands such as Pentasure, Obesigo, Pediagold and Nutrone.

The company has reported steady financial growth in recent years. Profit after tax rose to Rs 24.4 crore in FY25 from Rs 12.2 crore in FY24 and Rs 5.8 crore in FY23, while total income increased to Rs 331 crore.

At the upper end of the price band, Hexagon Nutrition is valued at around 15 times post-issue earnings.

Advertisement

Market participants will closely watch subscription trends in both issues as they could provide a signal on investor appetite for new listings after months of fluctuating market sentiment.

The broader market environment remains mixed. Indian equities have faced pressure this year from elevated crude oil prices, geopolitical tensions in West Asia and foreign institutional investor outflows. However, strong domestic liquidity and continued retail participation have helped support primary market activity.

SME segment

Apart from the mainboard issues, the SME segment is also expected to remain active next week.

Advertisement

Genxai Analytics plans to raise about Rs 55 crore through its NSE SME IPO, which opens on June 5 and closes on June 9. The issue is priced at Rs 110-116 per share. Vahh Chemicals will launch a fixed-price SME issue worth Rs 13.5 crore between June 4 and June 8 on the BSE SME platform.

Merritronix will also tap the SME market with a Rs 70 crore issue opening on June 1 and closing on June 3.

While SME offerings continue to attract investor interest, listing performance has remained mixed in recent months, making subscription quality and valuation discipline increasingly important factors for investors.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Advertisement
Continue Reading

Business

Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.46%

Published

on


Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.46%

Continue Reading

Business

Intellia Therapeutics – Steady Progress, Historic Commercial Approval In Sight

Published

on

Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight

Intellia Therapeutics – Steady Progress, Historic Commercial Approval In Sight

Continue Reading

Trending

Copyright © 2025